An update on the measurement and management of cholesterol with specific reference to secondary prevention of cardiovascular disease (CVD)

Keyphrases

• Cholesterol 100%
• Serum Cholesterol 100%
• Secondary Prevention of Cardiovascular Diseases 100%
• Specific Reference 100%
• Low-density Lipoprotein Cholesterol (LDL-C) 66%
• Non-high-density Lipoprotein Cholesterol (non-HDL-C) 66%
• Statins 33%
• Secondary Prevention 33%
• Myocardial Infarction 33%
• Therapeutic Intervention 33%
• Cardiovascular Disease 33%
• Cholesterol-lowering 33%
• HMG-CoA Reductase Inhibitors 33%
• Disease Outcome 33%
• Atorvastatin 33%
• Rosuvastatin 33%
• High-intensity Statin 33%
• High Cost 33%
• Ezetimibe 33%
• Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) 33%
• Death from Cardiovascular Diseases 33%
• Risk Factors for Coronary Artery Disease 33%
• New Therapies 33%
• Low Cholesterol 33%
• Non-communicable 33%
• Low-density Lipoprotein Cholesterol Level 33%
• Large Artery Atherosclerosis 33%
• Established Cardiovascular Disease 33%
• Cardiovascular Prevention 33%
• New Targets 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Cardiovascular Disease 100%
• Hydroxymethylglutaryl Coenzyme A Reductase Inhibitor 60%
• Low Density Lipoprotein Cholesterol 60%
• Lipoprotein 40%
• Disease 20%
• Atherosclerosis 20%
• Heart Infarction 20%
• Atorvastatin 20%
• Rosuvastatin 20%
• Ezetimibe 20%
• Coronary Artery Disease 20%
• Cerebrovascular Accident 20%